A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma
This phase II trial will be studying how well Apatinib working in patients with Hepatocellular carcinoma.
Advanced Hepatocellular Carcinoma
DRUG: Apatinib
TTP (Time to Progression), 8 weeks
Overall Survival, 8 weeks|DCR (Disease control rate, 8 weeks|ORR (objective response rate), 8 weeks|Serum alpha-fetoprotein (AFP) level, 8 weeks|QoL (quality of life): EORTC QLQ-C30, 8 weeks
This phase II trial will be studying how well Apatinib working in patients with Hepatocellular carcinoma.